OVOMET® Composition

• Ovomet® is an innovative product obtained fromremoving the eggshell and the membranethrough a patented and environmentally-friendlyprocess.

• Eggshell membrane is a natural protective barrierwhich contains many beneficial elements forhealth and wellness.

VIII. Sept-16

OVOMET® Composition

• OVOMET®’s Composition:

Hyaluronic Acid (4%)

Collagen (33-38%)

Glucosamine (2%)

Chondroitin sulfate (2%)

Keratin (1%)

Lysozyme (1%)

Other elements:

• More than 500 different proteins

Hyaluronic Acid

Collagen

Glucosamine

Chondroitin

Keratine

Lysozyme

Other elements

• Growth factor β

• Ovocalixin

• Ovocleidin

• Ovotransferrin

• Elastin

• Desmosine

• Isodesmosine

• Sulfur-bearing amino acids: Methionine, cysteine.

VIII. Sept-16

How does OVOMET® work?C

olla

gen

(33

-38

%) Mostly from type I;

which is needed by the vascular system, skin, tendons, ligaments, the joints’ cartilage and bones. It is synthesized to heal lesions.

Collagen type I is more absorbable and digestible than Collagen type II. Besides, it activates the synthesis of Hyaluronic Acid and endogen collagen in the cartilage and where it is necessary.

Hya

luro

nic

Aci

d(4

%) Very important for the skin

and joints’ cartilage. It is a “major player” in the skin wounds and damage recovery, and it is also important in the joints lubrication.

Several studies have proven that only the high weight Hyaluronic Acid molecules as the ones in Ovomet®(over 650kDa) is effective in joint and the skin health.

Ch

on

dro

itin

Su

lph

ate

(2%

) It is an effective protector of the cartilage, synovial membrane and sub chondral bone; the three main structures damaged by arthritis. Besides, it seems to stop and decrease some factors which produce the inflammatory processes.

Glu

cosa

min

e(2

%) It plays a main role in

the cartilage’s integrity maintenance. It activates the synthesis of collagen, endogen chondroitin sulphate and glucosamine precursors and reduces and stops the progression of the arthritis and osteoarthritis’ symptoms

Lyso

zym

e(1

%) It is an enzyme with

important antibacterial effects as well as a powerful activator of the immune system.

It’s essential to reactivate it after going under immunosuppressive treatments (for cancer or after an organ’s transplantation) and for modulating it in case of autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, etc…)

Other: more than 500 different proteins acting as physical and microbiological barrier.

• Keratine• Growth factor - β

• Ovocalixin• Ovocleidin

• Ovotransferrin• Elastin

• Desmosine• Isodesmosine

VIII. Sept-16

OVOMET® Synergy

• Ovomet® is more effective due to thesynergy of its compounds.

• There are several studies which provethat the components’ synergy it’s among5 and 6 times more effective than theeffects of the components themselves.

*GAGs: Hyaluronic acid, Keratin and Chondroitin sulfate**Other Components: Growth factor β, Ovocalixin, Ovocleidin, Ovotransferrin, Elastin, Desmosine and Isodesmosine

VIII. Sept-16

OVOMET® Synergy effect - Comparative analysis

References:

*Ruff et al. Clinical Rheumatology August 2009; 28 (8): 907-914.

**Garcia-Tabar et al. International Journal of Sport Nutrition and Exercise Metabolism 2016 (26) S1-S15.

**Garcia-Tabar et al. Archivos de Medicina del Deporte 2015; 32 (5): 314-334.

**Blasco JMI et al. Int. J. Clin. Rheumatol. (2016) 11(5), 077-081

***Walbroel et al. The nature network 2011.

****Schauss et al. Journal of Agricultural and Food Chemistry 2012; 60 (16):4096-4101.

A comparison between different chondroprotectors. The pain level using WOMAC is represented

50

60

70

80

90

100

0 days 28-35-30 days 60-70-50 days

100

81,4

68,0

100

76,4

62,0

100

72,9

57,3

Comparison: two commercial hydrolyzed collagens vs Ovomet®

Jointsol® 5g BioCell 2g Ovomet® 0.3g

0 días 28-35-30-días 60-70-50 días50

60

70

80

90

100

0 days 30 days 60-50 days

10096,1

85,2

100

72,9

57,3

Comparison: Commercial eggshell membrane vsOvomet®

Ovomet® 0.3gOther EggshellMembrane 0.5g

VIII. Sept-16

OVOMET® Synergy effect - Comparative Analysis

A comparison between different chondroprotectors. The pain level using WOMAC is represented

References:

*Lugo et al. Nutrition Journal (2016) 15:14.

**Garcia-Tabar et al. International Journal ofSport Nutrition and Exercise Metabolism2016 (26) S1-S15.

**Garcia-Tabar et al. Archivos de Medicinadel Deporte 2015; 32 (5): 314-334.

**Blasco JMI et al. Int. J. Clin. Rheumatol.(2016) 11(5), 077-08150

55

60

65

70

75

80

85

90

95

100

0 days 10 days 30 days 60-50 days 90 days 120 days 150 days 180 days

100

94,3

88,4

85,6

80,3

77,3

73,6

70,1

100

92

86,3

82,4

77,9

72,9

69,6

66,6

100

93,3

84,2

78,1

71,7

65,7

62,9

58,7

100

84,3

72,9

57,3

Comparison: placebo vs glucosamine+chondroitin vs native collagen vs Ovomet®

Placebo Gluc+Cond UC II® Ovomet®0 días 10 días 30 días 60-50 días 90 días 120 días 150 días 180 días

VIII. Sept-16

OVOMET ® 3 Benefits 1 Product

• Ovomet® shows 3 main benefits:

Anti-inflammatory Analgesic Joint regenerator

• It is specially effective in:

Helping in joint function. Strengthening joints. Reducing joint pain. Treating osteoarthritis and arthritis. Preventing joint lesions. It favours the activation and modulation

of the immune system.

VIII. Sept-16

DOSAGE

300 miligrams per day per person / 12 mg per Kg of pet per day

SHORT-TERM BENEFITS

Showing benefits from 7 to 10 days

NO NEED TO SUSPEND THE TREATMENT AND NO SIDE EFFECTS

Completely natural product; no contraindications described and it’s gluten-free

ABSENCE OF HEAVY METALS

Non-chemical, completely clean and Environmental-friendly process

OVOMET® Features

• Ovomet® most relevant features:VIII. Sept-16

WATER ACTIVITY

It is lower than 0.5% so its conservation is not affected

EXPIRATION DATE OF THE PRODUCT

24 months

PURITY

OVOMET® is over 95% membrane

OVOMET® Features

• Other biographical references of studies

Effects of Natural Eggshell Membrane (NEM) on Cytokine Production in Cultures of Peripheral Blood Mononuclear Cells Kathleen F. Benson and Gitte S. Jensen from NIS Labs,Klamath Falls, Oregon, USA. Kevin J. Ruff from ESM Technologies, LLC, Carthage, Missouri, USA

Eggshell membrane in the treatment of pain and stiffness from osteoarthritis of the knee: a randomized, multicentre, double-blind, placebo-controlled clinical study. Kevin J.Ruff & Anne Winkler & Robert W. Jackson & Dale P. DeVore & Barry W. Ritz

Egg Membrane as a New Biological DressJun. 25,2002ing in Split-Thickness Skin Graft Donor Sites: A Preliminary Clinical Evaluation. Jui-Yung Yang,MD; Shiow-ShuhChuang,MD;Wen-Guei Yang,MD;Pei-Kwei Tsay, PhD Presented at the 3rd Asian-Pacific Burns Conference (APBC) in Taipei, Taiwan, April 1-5, 2000. From the Department ofPlastic and Reconstructive Surgery. Chang Gung Memorial Hospital, Taipei. Received:; Accepted: Now. 25, 2002

VIII. Sept-16

Eggnovo’s StudiesC

linic

stu

die

s• Osteoarthritic/arthritic diagnosed people:

• Study1*: January2015• Study2:** October2015

• Runners*: Study January 2015

• Crossfitters*: Study January 2015

• Clinical synovitis study: March 2016

• Histological study: December 2015

• Absorption study: March 2016

• Capsules: March 2015• Snacks: October 2015• Diet with placebo: February 2016• Snacks with placebo: February 2016

• Skin hair and nails: Study February 2015

• Dermal Study: biophysical parameters (hydration, pigmentation, elasticity) 2016

* Publications: - Garcia-Tabar et al. International Journal of Sport Nutrition and Exercise Metabolism 2016 (26) S1-S15.- Garcia-Tabar et al. Archivos de Medicina del Deporte 2015; 32 (5): 314-334.- Blasco JMI et al. Int. J. Clin. Rheumatol. (2016) 11(5), 077-081

VIII. Sept-16

Studies Eggnovo

• Osteoarthritic/arthritic diagnosed people:

• Study 1*: January 2015• Study 2*: October 2015

• Runners*: Study January 2015

• Crossfitters*: Study January 2015

* Publications:

- Garcia-Tabar et al. Eggshell membrane in the treatment of pain and stiffness associated with joint and connective tissue disorders. International Journal of Sport Nutrition and Exercise Metabolism 2016 (26) S1-S15.- Garcia-Tabar et al. Suplementación con membrana de cáscara de huevo para tratar el dolor y la rigidez articular. Archivos de Medicina del Deporte 2015; 32 (5): 314-334.

- Blasco JMI et al. The Effect of Daily Administration of 300 mg of Ovomet® for Treatment of Arthritis in Elderly Patients. Int. J. Clin. Rheumatol. (2016) 11(5), 077-081

VIII. Sept-16

Results

Osteoarthritic and arthritic diagnosed people

“Before the Ovomet® intake, I could not go downstairs in themorning because of my knees stiffness. Nowadays, I can do itwithout problems.”(Woman 63 years old. Osteoarthritic diagnosed.)

Testimonials

VIII. Sept-16

Results

Runners

RESUMEN ESTUDIO RUNNERS

“When I took part in Ovomet® clinical study, I was almost sureto give up my Triathlon due to the problems with the 21 kmsrace. After the treatment, I could participate and finish anIronman in México” (Men, 38 years old. Athlete.)

Testimonials

VIII. Sept-16

Results

CrossfittersVIII. Sept-16

Results

Clinical study Los Manzanos Clinic in Logroño: Osteoarthritic patients

• Average age: 73.5 years-old.

• Medical reviews in days 0, 20 and 50 of treatment.

• Pain rate very acute at the beginning of the study

VIII. Sept-16

Results

Clinical study Los Manzanos Clinic in Logroño: Osteoarthritic patients

20,0

50,0

70,0

0

20

40

60

80

20 30 50

Perc

enta

ge o

f p

atie

nts

wit

nan

im

pro

vem

en

t o

f p

ain

eq

ual

or

mo

re t

han

2

0 %

Time (days)

Relative primary response of pain

60,0

80,0

95,0

0

20

40

60

80

100

20 30 50

Perc

enta

ge o

f p

atie

nts

wit

nan

im

pro

vem

ent

of

stif

fnes

s eq

ual

or

mo

re t

han

20

%

Time (days)

Relative primary response of stiffness

VIII. Sept-16

Results

Clinical study Los Manzanos Clinic in Logroño: Osteoarthritic patientsVIII. Sept-16

Experimental studies

• Clinical study synovitis. March 2016

• Histological study. December 2015.

• In vitro Absorption study. March 2016.

VIII. Sept-16

Experimental studies

SYNOVITISInflammation of thesynovial membrane

Variation of sinovial liquid Increase of the production Change in the composition

OSTEOARTHRITIC MODERATEPATIENTS

OSTEOARTHRITIC ACUTE

PATIENTSRUNNERS CROSSFITERS

INFLAMMATION, SWELLINGPainStiffnessFunction

DEGENERATION OF THE CARTILAGE

Lack of nutritionCatabolic metabolites

VIII. Sept-16

Experimental studies: synovitis

SYNOVITISSynovial membrane inflammation

Increase of the joint space

CARTILAGE DEGENERATION

Lack of nutritionCatabolic metabolites

Group of experimental animals: 40 dogs (30 ovomet® + 10 placebo)

Treated dogs with 15 mg ovomet® Kg-1 dog day-1

40 days of treatment

INFLAMMATIONPainStiffnessFunction

Flexion grade 10,3%

Muscular perimeter 7,8%

Pain 7,8%Inflammatory blood

markers 16%NO, TNF-α

Hip sonography

General improvement37,4%

Hip function 15,8%Before After

Joint Space48,8%

VIII. Sept-16

Experimental studies: histologic

In vivo arthrosis study UNILEON

% degeneratedcartilage

% cartilage loss % depth of cartilageloss

Degeneration score

23% 16% 33% 20%

Surgery to cause knee arthrosis. Knee histological preparations

16 rats (8 treated + 8 control)

Rats treated with 5 mg ovomet® Kg-1 rat day-1

18 weeks of treatment

VIII. Sept-16